Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
17 February 2023
Pictured: Chloe Whitehouse PhD, a Postdoctoral Fellow at MSD with the RASTRUM platform.
Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, has announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform.
Through this collaboration, novel bioprinting capabilities offered by RASTRUM™ will be utilised to create 3D in vitro models for the preclinical screening of neurodegenerative disease therapeutic candidates.
Inventia’s Founder and CEO, Dr Julio Ribeiro said: “Inventia is committed to working with MSD to establish better in vitro models for neurodegenerative diseases. By working together, we aim to establish new approaches to drug discovery and create more translatable models which bridge the gap between in vitro and in vivo preclinical studies.”
The RASTRUM™ platform is designed to enable the generation of highly reproducible cell models that closely mimic the human brain.
The collaboration aims to accelerate the drug discovery process by evaluating therapeutic candidates on 3D in vitro models of various neurological disorders, including Alzheimer’s disease and Parkinson’s disease.
“This collaboration with Inventia leverages MSD’s deep expertise in neuroscience and drug discovery with Inventia’s novel 3D bioprinting platform to develop more relevant and translational models of the brain with the aim of enhancing preclinical screening for neurodegenerative disease candidates,” said Dr. Jill Richardson, Executive Director of Biology, MSD, London.
About Inventia Life Sciences
Inventia is building bioprinters and formulating bioinks that together allow human cells to be printed in three- dimensional structures and help forward-thinking pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes.
The RASTRUM™ platform creates 3D cell cultures which closely imitate real human tissue in terms of its structure and behaviour across a range of disease states. The physiological complexity of these cell cultures provides an environment in which world-class research and discovery can occur, right in the researcher’s own lab.
Inventia Life Science Pty Ltd was the vision of Dr. Julio Ribeiro and founded by him with Dr. Aidan O'Mahony, Dr. Cameron Ferris and Peter Arthur in 2013 and is headquartered in Sydney, Australia.
The company recently opened its first US office and facility in Delaware.
Our BMTH program awarded $1M funding to Inventia Skin in 2020 to support development of the Ligō skin printing robot to revolutionise the approach to wound repair by enabling the rapid and precise delivery of regenerative cellular therapy products directly onto the wound site.
Inventia also made it onto the 2022 AFR BOSS Most Innovative Companies list.